Fluorescent composite molecular probe and application thereof

By designing a combination of donor and acceptor molecules in the FRET fluorescent probe, the FRET efficiency and stability of the fluorescent composite molecular probe are improved, the structural design problems in the prior art are solved, and efficient biological detection applications are realized .

CN118910241APending Publication Date: 2024-11-08PHOTONIC VIEW TECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410950062.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

It is difficult to achieve high efficiency and stability in structural design of existing FRET fluorescent probes, and traditional methods have problems such as poor water solubility and difficult synthesis, which affects their application in biological detection.

Method used

A fluorescent composite molecular probe consisting of FRET fluorescent unit and structural framework was designed. The number of donor molecules and acceptor molecules in the FRET fluorescent unit is not equal, and the excitation light wavelength of the acceptor molecules includes the emission light wavelength of the donor molecules. , and the emission spectrum of fluorescent donor molecules overlaps with the absorption spectrum of acceptor molecules, and this combination improves FRET efficiency and fluorescence intensity.

Benefits of technology

Achieve high-efficiency energy transfer (>70%) and high stability differentiated multi-level fluorescence intensity, simplifying the preparation process, suitable for applications in biological and medical fields, such as DNA sequencing and biomarker detection, with differentiated and multi-level Features of synthesis, specificity, luminescence stability and low cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004946965930000071
    Figure BDA0004946965930000071
  • Figure HDA0004946965940000011
    Figure HDA0004946965940000011
  • Figure HDA0004946965940000012
    Figure HDA0004946965940000012
Patent Text Reader

Abstract

The invention relates to the field of biological detection, in particular to a fluorescent composite molecular probe and application thereof. The fluorescent composite molecular probe provided by the invention comprises one or more Forster resonance energy transfer (FRET) fluorescent units, and the FRET fluorescent units comprise donor molecules and acceptor molecules with unequal numbers. The fluorescent composite molecular probe provided by the invention has the characteristics of high FRET (Fluorescence Resonance Energy Transfer) efficiency, stable luminescence, differentiation, multi-stage, specificity, easiness in preparation, high biological reaction compatibility and low cost under a single excitation wavelength and a single emission wavelength, and is suitable for detecting biomacromolecules (DNA (Deoxyribose Nucleic Acid), RNA (Ribose Nucleic Acid), MRI (Metal Oxide Semiconductor), MRI (Metal Oxide Semiconductor) and MRI). The invention can be applied to biological and medical fields such as protein (e.g., protein) sequencing, biomarker detection, protein fingerprint spectrum detection and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection, and in particular to a fluorescent composite molecular probe and application thereof. Background Art

[0002] Conventional fluorescent dye compounds have a lot of overlap between their excitation band and emission band, which will cause insufficient sensitivity and discrimination when detecting emitted fluorescence. Fluorescent groups with Stokes shift properties have a large degree of discrimination between their excitation wavelength and emission wavelength, which can greatly improve the sensitivity and discrimination of detection. However, general single fluorescent dye compounds with Stokes shift properties will face the challenges of poor water solubility and difficulty in synthesis; and modification measures to enhance water solubility will affect their spectral properties and cause peak shifts. FRET dyes based on the photophysical principle of Förster resonance energy transfer (FRET) can well achieve a large range of Stokes shift. Therefore, FRET technology has very important applications in bioanalysis, and can be used to study the structure and function of biological macromolecules, the interaction between molecules, the binding mechanism and binding kinetics of drug molecules, the signal transmission mechanism of molecular networks, etc.

[0003] The FRET efficiency and fluorescence stability of the probe will directly affect the luminescence efficiency, detection duration and detection sensitivity of the probe. Therefore, a high-efficiency and high-stability FRET fluorescent molecular probe is needed. Traditional FRET probes require a rigid structure to ensure high FRET efficiency, but a completely rigid FRET molecular structure is difficult to achieve in design. Summary of the invention

[0004] In view of the above-mentioned shortcomings of the prior art, an object of the present invention is to provide a fluorescent composite molecular probe and its use to solve the problems in the prior art.

[0005] To achieve the above-mentioned purpose and other related purposes, the present invention provides a fluorescent composite molecular probe, which is composed of a FRET fluorescent unit and a structural frame; the number of donor molecules and acceptor molecules contained in the FRET fluorescent unit is unequal; the FRET fluorescent unit is connected to the structural frame. Among them, the range of the excitation light wavelength of the acceptor molecule includes the range of the emission light wavelength of the donor molecule, and does not include the range of the excitation light wavelength of the donor molecule. The emission spectrum of the fluorescent donor molecule overlaps with the absorption spectrum of the acceptor molecule; the larger the overlapping area, the higher the FRET efficiency and the stronger the fluorescence intensity.

[0006] Preferably, the number of donor molecules in the FRET fluorescent unit is less than that of acceptor molecules, wherein the number of donor molecules is 1 or more.

[0007] The present invention also provides a labeling molecule, which comprises the aforementioned fluorescent composite molecular probe and a probe-binding substrate.

[0008] The present invention also provides the use of the aforementioned fluorescent composite molecular probe or the aforementioned labeling molecule in preparing sequencing, molecular diagnosis or molecular detection products.

[0009] As described above, the fluorescent composite molecular probe and its use of the present invention have the following beneficial effects:

[0010] The fluorescent composite molecular probe provided by the present invention achieves highly stable differentiated multi-level fluorescence intensity under the premise of efficient energy transfer (>70%). The present invention provides the design rules and preparation methods of fluorescent probes with differentiated multi-level fluorescence intensity under a single excitation wavelength and a single emission wavelength. Through the preparation method provided by the present invention, the fluorescent probe can be further connected to protein molecules and / or nucleotides, nucleotide analogs, so as to achieve specific labeling of biological macromolecules. The present invention adopts molecular biology technology and biological systems, and avoids the complex, time-consuming and costly organic synthesis process through the strategy of constructing fluorescent complexes, greatly simplifies the preparation and purification process of fluorescent molecular probes, and saves manpower, time and resource investment. The fluorescent composite molecular probe provided by the present application has the characteristics of differentiation, multi-level, specificity, stable luminescence, high FRET efficiency, easy preparation, high biological reaction compatibility and low cost.

[0011] The fluorescent composite molecular probe provided by the present invention is suitable for applications in the biological and medical fields, such as DNA sequencing, detection of biomarkers, and fingerprint spectrum detection of proteins. When performing DNA sequencing applications, four nucleotide analogs are distinguished by fluorescent composite molecular probes with predetermined, different levels of fluorescence emission intensity. When excited using an appropriate single excitation wavelength, the fluorescent composite molecular probe will produce a predetermined fluorescence emission intensity. During the DNA polymerization reaction, the identity of the nucleotide analog can be confirmed based on the grading of its fluorescence emission intensity, thereby determining the target nucleotide sequence and achieving DNA sequencing. The fluorescent molecular probe obtained by the design rules and preparation methods provided by the present invention can also be used to label a variety of antibody molecules. Through the immune reaction between antigens and antibodies occurring on the surface of the detection chip, specific labeling and identification of target proteins or protein post-translational modification sites can be achieved, thereby completing the detection of biomarkers or fingerprint spectrum detection of proteins. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1Schematic diagram showing the results that the FRET fluorescent unit in the form of nDmA (0 < n < m) in the present invention has a higher FRET efficiency than nDnA and nDmA (n > m > 0).

[0013] Figure 2 Schematic diagram showing the results that the FRET fluorescent unit in the form of nDmA (0 < n < m) in the present invention has a higher FRET efficiency and better fluorescence stability than nDnA and nDmA (n > m > 0), and by varying the numbers of n and m in the nDmA (0 < n < m) donor-acceptor combination, fluorescence intensities with differences can be obtained.

[0014] Figure 3 Schematic diagram showing the results that the fluorescent unit in the middle section of the constituent lines of the DNA structural framework in the present invention has better fluorescence stability and FRET efficiency than the fluorescent unit at the end of the constituent lines of the DNA structural framework. For the 1D2A FRET fluorescent unit, when the interval between D and A is 0 - 9 bp, the FRET efficiency is above 70%, and it has a higher FRET efficiency compared to the compound dye (CD). The FRET efficiency is the highest at a 3-bp interval, reaching 100%.

[0015] Figure 4 Schematic diagram showing the design forms of the FRET fluorescent units in the present invention, where the acceptor tested in the left figure is Cy5, and different donors correspond to one acceptor; the donor tested in the right figure is Cy3, corresponding to different acceptors.

[0016] Figure 5 Schematic diagram showing the results that various FRET fluorescent units can be obtained by varying the numbers of n and m in the present invention.

[0017] Figure 6 Schematic diagram showing the detection results of the annealing products of the DNA fluorescently labeled molecular probe and the fluorescence intensity of the FRET fluorescently labeled molecular probe in the present invention, where in the left figure, Lanes 1 - 9 are the annealing products of the DNA fluorescently labeled molecular probes under different fluorescence modification conditions; the right figure is the detection results of the fluorescence intensities of 9 groups of FRET fluorescently labeled molecular probes prepared based on the nDmA FRET fluorescent unit and its combination forms.

[0018] Figure 7 Schematic diagram showing the optical detection process and detection results of the immobilized FRET fluorescently labeled composite molecular probe in the present invention.

[0019] Figure 8 Schematic diagram showing an example of the structural framework composed of nucleic acid chains connected to the nDmA (0 < n < m) FRET fluorescent unit in the present invention.

[0020] Fig. 9Shown is a schematic diagram of the detection results of the purified FRET fluorescently labeled composite molecular probe in the present invention, where M: marker; Lane 1: sample before purification; Lane 2: washing flow-through fraction; Lane 3: eluted purified target fraction.

[0021] Fig.10 Shown is a flow chart and representative results of using nDmA (0 < n < m) FRET fluorescent probes with differential characteristics in the present invention to label nucleotide analogs and apply them to DNA sequencing.

[0022] Fig.11 Shown is a flow chart of using nDmA (0 < n < m) FRET fluorescent probes with differential characteristics in the present invention to label antibodies and apply them to immunoassay.

[0023] Fig.12 Shown is a schematic diagram of the results of the nDmA (0 < n < m) FRET fluorescent unit and its combination in the present invention to achieve differential multi-level fluorescence intensities at a single excitation wavelength and a single emission wavelength. Detailed implementation manners

[0024] The present invention provides a fluorescent composite molecular probe, which is composed of a Förster resonance energy transfer (FRET) fluorescent unit and a structural framework. The FRET fluorescent unit contains unequal numbers of donor molecules and acceptor molecules; the structural framework is a nucleic acid chain or a polypeptide chain; the FRET fluorescent unit is connected to the structural framework. Among them, the excitation light wavelength range of the acceptor molecule contains the emission light wavelength range of the donor molecule and does not contain the excitation light wavelength range of the donor molecule. The emission spectrum of the fluorescent donor molecule overlaps with the absorption spectrum of the acceptor molecule; the larger the overlapping area, the higher the FRET efficiency and the stronger the fluorescence intensity.

[0025] In some specific implementation manners, the number of donor molecules in the FRET fluorescent unit is less than that of acceptor molecules, and the number of donor molecules is more than 1.

[0026] Further, when the number of donor molecules in the FRET fluorescent unit is 1, the number of acceptor molecules ≥ 2; or, when the number of donor molecules in the FRET fluorescent unit is 2, the number of acceptor molecules ≥ 3; or, when the number of donor molecules in the FRET fluorescent unit is 3, the number of acceptor molecules ≥ 4.

[0027] In some specific implementation manners, the structural framework is a linear, two-dimensional multi-chain, two-dimensional planar or three-dimensional three-dimensional structure composed of a nucleic acid chain or a polypeptide chain. Among them, the FRET fluorescent unit is connected to the structural framework by a covalent bond.

[0028] Furthermore, the position of the FRET fluorescent unit is closer to the center of the constituent lines of the structural frame than to the end of the structural frame.

[0029] In some specific embodiments, the nucleic acid chains of the structural framework include deoxyribonucleic acid chains and ribonucleic acid chains, and also include other forms of artificially synthesized nucleic acid chains, such as peptide nucleic acid chains and threose nucleic acid chains. The nucleic acid chains of the structural framework are selected from DNA chain structures, planar or three-dimensional nanostructures formed by self-assembly through complementary base pairing, such as a double-stranded structure composed of two nucleic acid chains, a stem-loop structure, a triplex structure, a quadruplex structure, a multi-strand cross structure, a column structure, and a polyhedron structure formed by a single or multiple nucleic acid chains; or, a DNA three-dimensional structure formed by DNA origami technology, which is a planar or three-dimensional structure composed of one or more single-stranded circular nucleic acid chains as a scaffold and multiple short-chain nucleic acid chains; the planar structure is selected from a planar triangle or a planar polygon, and the three-dimensional structure is selected from a regular polyhedron or a polygonal three-dimensional wireframe.

[0030] In some specific embodiments, in the fluorescent composite molecular probe, when the structural framework is a nucleic acid chain, the donor molecule and the acceptor molecule in the FRET fluorescent unit are connected to the same nucleotide or to different nucleotides, with a gap. Specifically, the interval between the donor molecule and the acceptor molecule is 0-15bp. More specifically, the interval is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15bp. Preferably, the interval is 0-9bp. Preferably, the interval is 0-4bp.

[0031] In some specific embodiments, in the fluorescent composite molecular probe, when the structural framework is a nucleic acid chain, the interval between each FRET fluorescent unit in the fluorescent composite molecular probe, that is, the closest interval of the nucleotides connected to the donor molecule in each FRET fluorescent unit, is 5-35bp. Specifically, the interval is 5-10, 10-15, 15-18, 18-20, 20-22, 22-25, 25-30 or 30-35bp. Preferably, the interval is 18-22bp.

[0032] Preferably, the fluorescent composite molecular probe contains ≥1 FRET fluorescent unit. More preferably, the fluorescent composite molecular probe contains 2 FRET fluorescent units with the same or different numbers of donor molecules. Specifically, the fluorescent composite molecular probe contains 2 FRET fluorescent units with 1 donor molecule; or, the fluorescent composite molecular probe contains a FRET fluorescent unit with 1 donor molecule and a FRET fluorescent unit with 2 donor molecules; or, the fluorescent composite molecular probe contains a FRET fluorescent unit with 1 donor molecule and a FRET fluorescent unit with 3 donor molecules; or, the fluorescent composite molecular probe contains 2 FRET fluorescent units with 2 donor molecules; or, the fluorescent composite molecular probe contains a FRET fluorescent unit with 2 donor molecules and a FRET fluorescent unit with 3 donor molecules; or, the fluorescent composite molecular probe contains 2 FRET fluorescent units with 3 donor molecules.

[0033] In some embodiments, the donor molecule is selected from one or more of Cy3, Cy3.5, Cy5, Cy5.5, AF532, AF555, NED, AF568 or ATTO565. Preferably, the donor molecule is Cy3 and / or AF555.

[0034] In some embodiments, the receptor molecule is selected from one or more of Cy3.5, Cy5, Cy5.5, Cy5B, Quasar670, AF647 or ATTO647N. Preferably, the receptor molecule is Cy5B.

[0035] The present invention also provides a labeling molecule, which comprises the aforementioned fluorescent composite molecular probe and a probe-binding substrate.

[0036] In some embodiments, the probe binding substrate is selected from protein molecules, nucleotides or nucleotide derivatives, oligonucleotide chains, amino acids or amino acid derivatives, amino acid residues, polypeptide chains. Specifically, the protein molecule can be one or more of an antibody molecule, an antigen molecule or an enzyme molecule.

[0037] In some specific embodiments, the fluorescent composite molecular probe and the probe binding substrate in the labeling molecule are connected by one or more of the following methods: 1) covalent binding method: reaction binding of N-hydroxysuccinimide ester / imidate / aldehyde / isocyanate and amino group, reaction binding of maleimide / haloacetyl / pyridine dithiol and thiol, reaction binding of hydrazide / alkoxyamine and carbonyl, photoreaction binding of aziridine and aromatic azide, reaction binding of azide and alkyne / phosphine; 2) non-covalent binding method: reaction binding of biotin and avidin, antibody and antigen binding, complementary connection of DNA nucleotides, connection of nucleic acid aptamer and its corresponding binding protein, binding of carbohydrate and lectin, binding of glutathione and GTS, protein-protein interaction or polypeptide chain-protein interaction.

[0038] The present invention also provides the use of the aforementioned fluorescent composite molecular probe or the aforementioned labeling molecule in preparing sequencing products, molecular diagnosis or molecular detection products.

[0039] In some specific embodiments, the sequencing product, molecular diagnosis or molecular detection product can be one or more of a DNA sequencing product, an RNA sequencing product, a DNA / RNA detection product, a protein detection product, an antigen detection product or an antibody detection product.

[0040] In some specific embodiments, the sequencing product, molecular diagnosis or molecular detection product may also include one or more of a buffer reagent, a surfactant or a preservative.

[0041] In some specific embodiments, the buffer reagent can be a phosphate buffer reagent. The phosphate buffer reagent is used to provide stable enzymatic reaction conditions. The surfactant is used to solubilize and disperse the solute to promote the enzymatic reaction. The preservative is used to control the growth of microorganisms in the test product.

[0042] The phosphate in the phosphate buffer reagent is selected from potassium phosphate or sodium phosphate. The potassium phosphate and sodium phosphate are selected from any one or more of potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium phosphate, sodium dihydrogen phosphate and disodium hydrogen phosphate.

[0043] The surfactant is a substance containing both a hydrophilic group and a hydrophobic group to significantly reduce the surface tension of the target solution. The surfactant is selected from any one or more of stearic acid, sodium dodecylbenzene sulfonate, quaternary ammonium compounds, lecithin, amino acid type, betaine type, alkyl glucoside, fatty acid glyceride, fatty acid sorbitan or polysorbate.

[0044] The preservative can be self-produced or commercially available. Preferably, the preservative is any one or more of the commercial ProClin series preservatives ProClin150, 200, 300 or 5000. More preferably, the preservative is ProClin300.

[0045] In the present invention, the term "Foster resonance energy transfer" is referred to as FRET, which is a non-radioactive energy transfer process, and its basic principles are as follows: 1. Excite the donor: When the donor molecule is excited by light, it transitions from the ground state to the excited state; 2. Energy transfer: If the acceptor molecule is in the vicinity of the donor molecule (usually within 1-10 nanometers), the donor molecule can transfer energy to the acceptor molecule in a non-radiative manner. This process does not require the participation of photons, so it is called non-radioactive energy transfer; 3. Acceptor excitation: After the acceptor molecule receives energy, it is excited to its excited state; 4. Fluorescence emission: When the acceptor molecule returns to the ground state from the excited state, it will emit lower energy light, which is the fluorescence ultimately used for detection.

[0046] In the present invention, the term "nucleotide derivatives" refers to molecules having a chemical structure similar to that of natural nucleotides, including a sugar molecule and a nitrogenous base, such as zidovudine, cytarabine or 2'-O-methyl nucleotides.

[0047] In the present invention, the term "DNA" is usually a common abbreviation for DNA, which is deoxyribonucleic acid. It is a nucleic acid molecule, i.e., a polymer composed of nucleotides. These nucleotides are usually deoxyadenosine monophosphate, deoxythymidine monophosphate, deoxyguanosine monophosphate and deoxycytidine monophosphate monomers, which themselves are composed of a sugar moiety (deoxyribose), a base moiety and a phosphate moiety, and are polymerized by a characteristic backbone structure. Usually, the backbone structure is formed by a phosphodiester bond between the sugar moiety of the first nucleotide, i.e., deoxyribose, and the phosphate moiety of the second adjacent monomer. The specific order of monomers, i.e., the order of bases connected to the sugar / phosphate backbone, is referred to as a DNA sequence. DNA can be single-stranded or double-stranded. In a double-stranded form, the nucleotides of the first chain are usually hybridized with the nucleotides of the second chain, for example, by A / T base pairing and G / C base pairing.

[0048] In the present invention, the term "DNA origami technology" refers to the use of DNA self-assembly technology to complete planar or three-dimensional DNA nanostructures in accordance with the principle of complementary base pairing. Generally, DNA origami is to use long single-stranded DNA (such as M13 phage DNA) as a "scaffold" and hundreds or thousands of short-stranded DNA as "staples" to controllably fold the long single-stranded DNA into various one-dimensional, two-dimensional or three-dimensional DNA nanostructures. With the development of DNA origami technology, a single long DNA chain or multiple mutually paired short DNA chains can also be used as assembly elements to assemble into any DNA nanostructure through complementary base pairing.

[0049] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0050] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.

[0051] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0052] Example 1 Preparation of fluorescent composite molecules

[0053] 1.1 Preparation and detection methods of DNA fluorescent probes

[0054] Principle and method: Custom-synthesized commercial oligonucleotide chains can be conveniently modified with fluorescent dyes and active groups at preset sites. A set of complementary oligonucleotide chains are mixed and annealed, and can spontaneously assemble to form DNA linear, planar or three-dimensional structures, thereby obtaining DNA fluorescent molecules with different fluorescent units and various modification conditions. Depending on the different charge properties or molecular weights, the annealing products can be separated and purified by high-performance liquid chromatography using anion exchange chromatography columns or size exclusion chromatography columns.

[0055] Materials and reagents: Oligonucleotide chains (100 μM) with preset fluorescent dyes and active groups were custom synthesized, and representative sequence information can be found in Table 1. 10×TE buffer: 100 mM Tris pH 7.8, 50 mM NaCl, 0.1 mM EDTA. 10×DNA loading buffer, purchased from Nanjing Novozyme Biotechnology Co., Ltd., catalog number P022-01. 50×TAE Buffer, agar powder, and DL10000 DNA Marker were purchased from Yisheng Biotechnology (Shanghai) Co., Ltd., catalog numbers 60116ES76, 70101ES76, and 10505ES60, respectively. Agilent PLRP-S The HPLC column was purchased from Agilent Technologies Inc. The mobile phase formula of HPLC: Buffer A is 0.1 mol / L acetic acid hexylamine aqueous solution, pH=7.0, 10% urea; Buffer B is acetonitrile.

[0056] Table 1 Representative oligonucleotide chain sequences

[0057]

[0058] Preparation and testing steps:

[0059] 1) A group of fluorescently modified oligonucleotide chains were mixed in 1X TE buffer solution in an equimolar ratio.

[0060] 2) Run the annealing program at 95°C for 5 min; 0.1°C / s to 60°C, 60°C for 2 h; 0.1°C / s to 50°C, 50°C for 2 h; 0.1°C / s to 4°C.

[0061] 3) Prepare a 2.0% agarose gel and run it at 100-110V for more than 1 hour. Use a gel imager to detect the annealing efficiency by the DNA bands with the corresponding molecular weight after annealing. The results are shown in the example. Figure 6 .

[0062] 4) Using high performance liquid chromatography, the annealing product is separated and purified by an anion exchange chromatography column or a size exclusion chromatography column. When an anion exchange column is used, the product in step 2 can be prepared into a 2 mg / mL solution, loaded into an ion pair reverse phase chromatography, and the mobile phase is run at a flow rate of 1 mL / min. The product at the ultraviolet (UV) absorption value of 260 nm is collected by Agilent 1290 Infinity II preparative liquid chromatograph, and the purity of the purified product is analyzed by the supporting software.

[0063] 1.2 Spectral test method for detecting FRET efficiency, light intensity and photostability

[0064] Principle and method: This method builds a detection device for 543nm laser excitation, collects 500-800nm ​​fluorescence signals through a spectrometer, and continuously collects and processes the FRET efficiency, light intensity and light stability of the FRET fluorescence unit obtained in method 2.1. This implementation method uses the area integral of the peak area of ​​the fluorescence spectrum to characterize the fluorescence intensity, and uses the change in fluorescence intensity over a continuous test of 30 minutes to characterize the fluorescence stability. The FRET efficiency is expressed by the formula Calculate, F DA represents the fluorescence spectrum area of ​​the donor when the acceptor is present, F D Represents the fluorescence spectrum area when only the receptor is present.

[0065] Apparatus and Materials:

[0066] Maya2000Pro spectrometer, 543nm laser, Thorlabs PM100D optical power meter, Shufu quartz micro-cuvette (1cm optical path).

[0067] Testing steps:

[0068] 1) Place a 1 cm optical path cuvette in the optical path, place the center of the cuvette directly toward the light source, use a 543 nm laser to optimize the collection optical path, connect the spectrometer, and adjust the filter to maximize the laser intensity of the spectrometer.

[0069] 2) Use a power meter to adjust the laser power to the ideal range and set the corresponding integration time and continuous acquisition time in the spectrometer software.

[0070] 3) Mix the sample to be tested and the anti-fading system and add them to the cuvette, making sure there are no bubbles in the solution. Collect the spectral data within the continuous acquisition time.

[0071] 4) Multiple DNA fluorescent probes were tested in parallel under the same experimental conditions, and each group of experiments was repeated more than three times.

[0072] 5) The collected spectral data were processed and visualized by MATLAB to characterize the FRET efficiency, light intensity and photostability of the DNA fluorescent probe. Representative experimental results are shown in Figure 2 and Figure 3 .

[0073] 1.3 Preparation and purification of fluorescent labeled composite molecular probes

[0074] Principle and method: Through DNA hybridization, multiple donor-receptor combinations and precise control of the spacing between donors and receptors can be achieved, so that DNA fluorescent probes can be connected to biological macromolecules in various ways such as covalent or non-covalent methods, including but not limited to the reaction binding of N-hydroxysuccinimide ester / imidate / aldehyde / isocyanate with amino groups, the reaction binding of maleimide / haloacetyl / pyridinyldithiol with thiol, the reaction binding of hydrazide / alkoxyamine with carbonyl, the photoreaction binding of aziridine and aromatic azide, the reaction binding of azide compounds with alkyne / phosphine, etc.; non-covalent binding methods such as biotin and its bound protein, avidin, streptavidin, neutravidin and other binding proteins; antibody and antigen binding, DNA nucleotide complementary connection, nucleic acid aptamer and its corresponding binding protein connection, carbohydrate and lectin binding, glutathione and GTS binding, protein-protein interaction, polypeptide chain-protein interaction, etc. In this method, the DNA fluorescent probe obtained by method 1.1 forms a complex with the protein to be labeled through the affinity binding of ligand and receptor, and an anion column is used to separate the fluorescent composite molecular probe from the free protein substrate and impurities to obtain a high-purity fluorescent labeled composite molecular probe.

[0075] Materials and Reagents: explorer was purchased from GE, and HiTrap Q HP anion exchange chromatography column was purchased from Cytiva, with the catalog number 29051325. TM Protein concentrator tubes and protein markers were purchased from Thermo Fisher Scientific, with catalog numbers 88513 and 26616, respectively. Streptavidin protein and 12% high-resolution precast gel were purchased from Yisheng Biotechnology (Shanghai) Co., Ltd., with catalog numbers 35100ES08 and 36247ES10, respectively. Buffer A formula: 10 mM Tris-HCl, pH = 7.5. Buffer B formula: 10 mM Tris-HCl, 1.5 M NaCl, pH = 7.5.

[0076] Preparation and separation and purification steps:

[0077] 1) The protein sample and the DNA fluorescent probe prepared by method 2.1 were mixed in equal proportions and incubated at 20°C for 2 h to allow the affinity binding between the two to fully occur.

[0078] 2) Dilute the incubated sample to 5 times the original volume using buffer A.

[0079] 3) Set the AKTA flow rate to 10 mL / min and flush the system with deionized water. The flushing liquid volume exceeds 5 times the system volume. Connect the HiTrap Q HP anion column at a flow rate of 0.5 mL / min. Adjust the flow rate to 1 mL / min to flush the anion exchange column HiTrap Q HP for more than 10 column volumes.

[0080] 4) Replace deionized water with buffer A, and equilibrate the system and the anion column at 1 mL / min to fill the system and the ion column with buffer A.

[0081] 5) After flushing the sample loop with buffer A, use a syringe to draw the sample. After exhausting the air, inject the sample in the sample addition mode, then adjust to the manual loading mode and run buffer A at a flow rate of 1 mL / min. After the sample enters the system, the UV value and conductivity value both increase. After the UV value and conductivity value are balanced to the baseline, remove the syringe.

[0082] 6) Elute the sample with a mixed solution of buffer A and buffer B, set the buffer B to increase in gradient from 0% to 100%, the total liquid volume during the elution process is 50 times the column volume, set the elution rate to 0.5 mL / min, and collect the target components.

[0083] 7) The collected samples were concentrated by ultrafiltration, and some samples were taken for quantification by UV absorption spectrum and SDS-PAGE separation and staining. Representative test results are shown in Fig. 9 .

[0084] 1.4 Optical detection of immobilized fluorescently labeled composite molecular probes

[0085] Principle and method: The fluorescently labeled composite molecular probe purified in method 1.3 is fixed on the surface of the detection glass slide in a covalent or non-covalent manner by chemical or biological methods, and its optical signal is observed and recorded by a total internal reflection fluorescence microscope or a confocal fluorescence microscope. In this implementation method, the surface of the detection chip is modified by biotin, and the fluorescently labeled composite molecular probe with streptavidin protein is fixed on the surface of the detection glass slide through the binding of biotin and streptavidin, and then placed under a total internal reflection fluorescence microscope or a confocal fluorescence microscope for detection.

[0086] Materials and reagents: Vacuum plasma was purchased from Guangzhou Shanzhun Technology Co., Ltd., model VP-R5. Silane-PEG-Biotin was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. Concentrated sulfuric acid solution, 30% hydrogen peroxide solution, and anhydrous ethanol were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0087] Fixation and detection steps:

[0088] 1) Slide treatment: Take 70 mL of concentrated sulfuric acid solution and 30 mL of 30% hydrogen peroxide solution. Slowly pour the hydrogen peroxide into the concentrated sulfuric acid solution while stirring. Immerse the slide to be cleaned in it and soak and clean for half an hour at room temperature. Take out the slide cleaned by piranha solution, rinse it with deionized water, put it into absolute ethanol and ultrasonically clean for 2 min at room temperature, take it out and dry it, and put it into a vacuum plasma device for O2 plasma for 2 min.

[0089] 2) Slide modification: Take out the treated slide and soak it in a 6 mg / mL Silane-PEG-Biotin solution, incubate at room temperature for 4 h, and wash the surface with a large amount of deionized water after incubation.

[0090] 3) Fixation of fluorescently labeled composite molecules: Spread the fluorescently labeled composite molecules conjugated with streptavidin protein on the surface of the modified slide. After co-incubation for 1 h, wash it multiple times with PBST solution to remove non-specific binding.

[0091] 4) Observe and record the fluorescence scintillation points using a total internal reflection fluorescence microscope or a confocal fluorescence microscope, and perform continuous signal acquisition. Apply the same experimental conditions to different

[0092] 5) Use ImageJ and MATLAB software to process and analyze the acquired signal images. Representative results are shown in Figure 7 , and the results show that the DNA fluorescent probe provided by the present invention can achieve the differentiation of multi-level fluorescence intensities at high resolution.

[0093] Example 2 Screening of various parameters in the fluorescent composite molecule

[0094] 2.1 For FRET fluorescent units with nDmA, 0 < n < m, they have the best FRET efficiency and fluorescence stability; the change in their number can correspond to different fluorescence intensities

[0095] Using the DNA backbone-based FRET method, with a donor molecule (Donor, D) and an acceptor molecule (Acceptor, A), Stokes shift can be achieved. Usually, the FRET fluorescent unit adopts the form of 1D1A. In the embodiment, a fluorescent unit form of nDmA is proposed. Through fluorescence spectrum testing, this embodiment compares the fluorescence intensity, FRET efficiency, and fluorescence stability of three FRET fluorescent units: 1D1A, 1D2A, and 2D1A. The test results show that 1D2A as a fluorescent unit has a higher FRET efficiency than 1D1A and 2D1A. The fluorescence intensity of 1D1A and 2D1A continuously decays with the extension of laser irradiation time, while 1D2A shows better fluorescence stability. The 2D3A fluorescent unit following the same design rule also shows excellent FRET efficiency and fluorescence stability, and its fluorescence intensity increases compared with 1D2A. Therefore, we find that compared with the conventional 1D1A donor-acceptor combination or nDmA (n>m>0) donor-acceptor combination, the nDmA (0<n<m) donor-acceptor combination shows better FRET efficiency and fluorescence stability and is the FRET fluorescent unit with the best performance. At the same time, by changing the numbers of n and m in the nDmA (0<n<m) donor-acceptor combination, multiple FRET fluorescent units with different fluorescence intensities can be obtained, such as Figure 1 and Figure 2 shown.

[0096] In addition, in this embodiment, it is also verified that the combination of FRET fluorescent units can achieve different multi-level fluorescence intensities at a single excitation wavelength and a single emission wavelength, such as Fig.12 shown.

[0097] 2.2 The fluorescence stability of the FRET fluorescent unit located in the middle section of the DNA backbone is better than that at the end of the DNA backbone

[0098] Fluorescent group modification is common at the ends of the DNA backbone. In this embodiment, the fluorescence spectrum performance of the 1D2A FRET fluorescent unit in two cases, namely at the end of the DNA backbone and in the middle section of the DNA backbone, is compared. The test results show that the fluorescence unit located in the middle section of the DNA backbone has better fluorescence stability and FRET efficiency than the fluorescence unit located at the end of the DNA backbone. Therefore, by modifying the FRET fluorescent unit in the middle section of the DNA backbone, a fluorescent probe molecule with better performance can be obtained, such as Figure 3 shown.

[0099] 2.3 Changes in the spacer distance between the donor and the acceptor can correspond to different fluorescence intensities

[0100] In this embodiment, the combination of fluorescent donor and acceptor placed in the middle section of the DNA backbone was compared with the Cy3-Cy5 compound dye (Chemical Dye, CD) obtained by chemical synthesis in terms of luminescence intensity and FRET efficiency. The test results show that the donor-acceptor combination based on the DNA backbone can exhibit better FRET efficiency than the compound dye. We tested a series of spacings between D and A, including 0bp, 1bp, 2bp, 3bp, 4bp, 6bp, 9bp, 12bp, 15bp, and 24bp; when both the donor and the acceptor are located in the middle section of the DNA backbone and the spacing of the fluorescent modification molecules is 0 - 9bp, the FRET efficiency > 70%, which is significantly better than the compound dye (CD); especially when the spacing between the donor and acceptor fluorescent modification molecules is 3bp, there is no emission peak at the emission peak wavelength band of 560nm of the donor molecule, and at this time, the FRET efficiency reaches up to 100%, as Figure 3 shown.

[0101] Meanwhile, this embodiment found that in the FRET fluorescent unit of nDmA (0 < n < m), the change in the spacing distance between the donor and the acceptor corresponds to different fluorescence intensities. For example, in the 1D2A FRET fluorescent unit (the spacing distances between the donor and the acceptor are 1bp and 3bp respectively) located in the middle section of the DNA backbone, although both have excellent fluorescence stability, the latter exhibits higher fluorescence intensity and FRET efficiency compared to the former. Therefore, by adjusting the spacing distance between the donor and the acceptor in nDmA (0 < n < m), FRET fluorescent units with different fluorescence intensities can be obtained; when the spacing is 3bp, its FRET efficiency can reach 100%, and it has higher fluorescence intensity, as Figure 3 shown.

[0102] 2.4 Changes in the types of donor and acceptor fluorescent molecules can correspond to different fluorescence intensities

[0103] This embodiment also respectively compared and tested three donor fluorescent molecules (Cy3, AF532, AF555) and three acceptor fluorescent molecules (Cy5, Cy5B, Quasar670). This embodiment found that Cy3 and AF555 exhibited better FRET efficiency and fluorescence intensity than AF532 under the target excitation wavelength; Cy5B exhibited higher fluorescence intensity than Cy5 and Quasar670, and the fluorescence intensities of Cy5 and Quasar670 were close. Therefore, this embodiment preferentially selects Cy3 and AF555 as donor fluorescent molecules. By selecting different types of donor and acceptor fluorescent molecules, FRET fluorescent units with different fluorescence intensities can be obtained, as Figure 4 shown.

[0104] In addition, for the FRET fluorescent units obtained by following the above design rules, combinations of different types of FRET donor and acceptor fluorescent molecules all exhibit good FRET efficiency (>70%) and fluorescence stability. Therefore, the benefits brought by the design rules of the FRET fluorescent units proposed in the present invention are applicable to various types of FRET donor and acceptor fluorescent molecules. The donor probe can be Cy3, Cy3.5, Cy5, Cy5.5, NED, AF568, ATTO565, etc., and the acceptor probe can be Cy3.5, Cy5, Cy5.5, quasar670, AF647, and ATTO647N, etc.

[0105] 2.5 By combining multiple FRET fluorescent units, fluorescent molecular probes with differentiated multi-level fluorescence intensities can be obtained, which are suitable for characteristic labeling and detection of target molecules.

[0106] Based on the design rules of the FRET fluorescent units of nDmA, 0 < n < m (the distance between the donor and the acceptor is 0 - 9 bp, preferably 3 bp), multiple FRET fluorescent units are obtained by varying the numbers of n and m. In this example, these fluorescent units are placed in the middle section of the DNA backbone, and the distance between two FRET fluorescent units is greater than 10 bp (preferably 20 bp), and different fluorescent molecular probes are combined, such as Figure 5 shown. Fluorescence spectra of these fluorescent molecular probes were detected in this example, and it was confirmed that they exhibited differentiated multi-level fluorescence intensities at a single excitation wavelength and a single emission wavelength. By adjusting the number, distance, type, and site of the donor and the acceptor according to the above design rules, while effectively improving the FRET efficiency and fluorescence stability, changes in fluorescence intensity can be achieved, such as Figure 6 shown.

[0107] This embodiment further uses the fluorescent molecular probe to label multiple biological macromolecules, such as protein molecules, nucleotide analogs or antibody molecules, in a covalent or non-covalent manner. There are many ways to connect the fluorescent molecular probe to the biological macromolecule, including but not limited to the reaction of N-hydroxysuccinimide ester / imidate / aldehyde / isocyanate with amino groups, the reaction of maleimide / haloacetyl / pyridine dithiol with thiol, the reaction of hydrazide / alkoxyamine with carbonyl, the photoreaction of aziridine and aromatic azide, the reaction of azide with alkyne / phosphine, and other covalent binding methods; biotin and its binding protein, avidin, streptavidin, neutravidin and other binding proteins, etc.; antibody binding to antigen, DNA nucleotide complementary connection, nucleic acid aptamer and its corresponding binding protein connection, carbohydrate binding to lectin, glutathione binding to GTS, protein-protein interaction, polypeptide chain-protein interaction, etc. We have carried out fixed fluorescence detection on these biological macromolecules with different fluorescent labeling characteristics. The test results show that the differentiated multi-level fluorescence intensity characteristic marker has extremely high resolution. The above fluorescent molecular probe can be used to mark and identify biological macromolecules, such as Figure 7 shown.

[0108] 2.6 DNA backbones with different spatial structures

[0109] Researchers with relevant professional knowledge or in the corresponding technical field can easily apply the design rules of the above-mentioned FRET fluorescent units and their combinations to structural frameworks composed of nucleic acid chains or polypeptide chains with other spatial structural characteristics other than DNA double-stranded structures, such as linear, two-dimensional multi-stranded, two-dimensional plane or three-dimensional structure. The nucleic acid chains include deoxyribonucleic acid chains and ribonucleic acid chains, and also include other forms of artificially synthesized nucleic acid chains, such as peptide nucleic acid chains and threose nucleic acid chains. The structural framework composed of the nucleic acid chains includes, but is not limited to, DNA chain structures, planar or three-dimensional nanostructures formed by self-assembly through complementary base pairing, such as double-stranded structures composed of two nucleic acid chains, stem-loop structures, triplex structures, quadruplex structures, multi-stranded cross structures, pillar structures, and polyhedral structures formed by single or multiple nucleic acid chains; or, a DNA three-dimensional structure formed by DNA origami, which is a planar or three-dimensional structure composed of one or more single-stranded circular nucleic acid chains as a scaffold and multiple short-chain nucleic acid chains; the planar structure is selected from a planar triangle or a planar polygon, and the three-dimensional structure is selected from a regular polyhedron or a polygonal three-dimensional wireframe. See some example figures. Figure 8 .

[0110] Example 3 Application of fluorescent composite molecules

[0111] 3.1 Application of fluorescent labeled composite molecular probes in DNA sequencing

[0112] Principle and method: Labeled nucleotide analogs can be used as substrates for the polymerization reaction of DNA polymerase. In the process of synthesizing the complementary chain of the DNA template, the specific signals of the nucleotide analogs are recorded and identified, thereby realizing the determination of the DNA template sequence. As described in the principle of 1.3 in Example 1, the connection method between the nucleotide analogs and their markers includes various methods such as covalent or non-covalent. In this application example, the four nucleotide analogs of A, T, C, and G are connected to the corresponding DNA fluorescent probes through the affinity between the ligand and the receptor. The purified nucleotide analogs with corresponding fluorescence intensity serve as substrates for DNA polymerase and participate in the synthesis of the complementary chain of the DNA template. By using a total internal reflection fluorescence microscope or a confocal fluorescence microscope to collect the real-time fluorescence signals occurring on the sequencing chip, the information of the corresponding nucleotides on the complementary chain of the DNA template at the corresponding site during the synthesis process can be obtained. By analyzing the collected fluorescence data, the sequence information of the synthetic chain complementary to the DNA template can be obtained, thereby realizing the sequence determination of the DNA template, such as Fig.10 shown.

[0113] Materials and Reagents:

[0114] Pierce TM Protein concentrator tubes were purchased from Thermo Fisher Scientific, catalog number 88513. The replacement buffer formula was: 50 mM Tris-HCl pH 7.5, 5 mM MgCl2. Explorer was purchased from GE, Pierce TM Protein concentrators and were purchased from Thermo Fisher Scientific, with catalog numbers 88513, respectively. HiTrap Desalting columns were purchased from Cytiva Life Sciences (Shanghai) Co., Ltd. Engineered DNA polymerase; custom-synthesized nucleotide analogs; Lambda DNA templates were purchased from NEB, catalog number N3011S; custom-synthesized sequencing adapters and sequencing primers; DNA polymerase reaction buffer containing metal ions; and fluorescence antiquenching system. The sequencing chip was a proprietary chip of Shanghai Jinguan Technology Co., Ltd.

[0115] Steps:

[0116] 1) The various fluorescent composite molecular probes prepared in method 1.3 of Example 1 were co-incubated with the corresponding nucleotide analogs at a molar ratio of 1:4 at 4° C. for 4 h.

[0117] 2) The reaction solution was transferred to a concentration tube and centrifuged at 8000 rpm, 4°C, for 40 min; and washed with a replacement buffer.

[0118] 3) Collect the washed products and load them into a HiTrap Desalting column, run the replacement buffer at a flow rate of 1 mL / min, collect the products with an ultraviolet (UV) absorption value of 260 nm, and detect the products by PAGE, thereby obtaining high-purity nucleotide analogs with corresponding fluorescent probes.

[0119] 4) constructing a DNA polymerase-template-primer complex, fixing it on a sequencing chip by covalent or non-covalent means, and cleaning the non-specific binding on the chip surface.

[0120] 5) preparing a mixed system containing metal ions, pH buffer, anti-quenching system and the fluorescently labeled nucleotide analog obtained in step 3, and initiating a DNA polymerization reaction.

[0121] 6) Observe and record the fluorescent flashing spots on the sequencing chip through a total internal reflection fluorescence microscope or a confocal fluorescence microscope to continuously collect signals.

[0122] 7) Perform data processing and analysis on the collected signal images to obtain real-time fluorescence signals of the corresponding sites, identify the corresponding nucleotide analogs through fluorescence characteristics, and obtain the information of the corresponding nucleotides on the complementary chain of the DNA template at the corresponding site during the synthesis process. Representative results are shown in Fig.10 .

[0123] 3.2 Application of fluorescent labeled complex molecules in immunoassays

[0124] Principle and method: In this example, different fluorescently labeled composite molecular probes are connected to three immune T cell typing-related biomarkers, CD3, CD8 and CD25, respectively, by the method described in method 1.3 of Example 1. Through the antigen-antibody immune reaction, the specific detection of CD3, CD8 and CD25 proteins in the sample can be achieved. By combining the standard curve, the three biomarkers in the sample can be further quantitatively analyzed, such as Fig.11 Shown

[0125] Materials and reagents: Two CD3 antibodies, two CD8 antibodies, and two CD25 antibodies were provided by the corresponding antibody manufacturers.

[0126] Steps:

[0127] 1) By the method 1.3 in Example 1, a plurality of fluorescent composite molecular probes are respectively connected to a corresponding CD3 antibody, a CD8 antibody and a CD25 antibody, so that the three detection antibodies are provided with preset and specific fluorescent labeled probes.

[0128] 2) The surface of the detection chip is treated, and another type of capture antibodies CD3 antibody, CD8 antibody and CD25 antibody without fluorescent labeled probes are fixed on the surface of the detection chip by covalent or non-covalent means.

[0129] 3) After the incubation is completed, the chip surface is washed several times, and a blocking buffer containing 5% BSA is applied and incubated at room temperature for 1 hour to block non-specific binding sites. The chip surface is then washed several times.

[0130] 4) The sample to be tested is introduced into the sample pool from the microfluidic inlet and incubated at room temperature for 1 hour, so that the immune T cells carrying CD3 protein, CD8 protein and CD25 protein in the sample can specifically bind to the capture antibody fixed on the chip surface.

[0131] 5) The chip surface was washed several times with PBST solution to remove non-specifically adsorbed impurities.

[0132] 6) The detection antibodies CD3, CD8 and CD25 with specific fluorescent labeled probes are diluted with blocking buffer and incubated with the chip surface at room temperature for 1 hour, so that the detection antibodies with specific fluorescent labeled probes are fully combined with the sample to be tested.

[0133] 7) Use PBST solution to wash the blocked chip surface multiple times.

[0134] 8) Place the chip under a total internal reflection fluorescence microscope or a confocal fluorescence microscope to scan and record the real-time fluorescence signal of the detection area.

[0135] 9) The fluorescent labeling feature can be used to distinguish the three biomarkers in the same sample, and by comparing the pre-made standard curve, the samples with different biomarkers can be further quantitatively analyzed.

[0136] The above examples are for the purpose of illustrating the embodiments disclosed by the present invention and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and the variations of the methods in the invention are obvious to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of the present invention.

Claims

1. A fluorescent composite molecular probe, characterized in that: The fluorescent composite molecular probe is composed of a FRET fluorescent unit and a structural frame; the FRET fluorescent unit contains unequal numbers of donor molecules and acceptor molecules; the structural frame is a nucleic acid chain or a polypeptide chain; and the FRET fluorescent unit is connected to the structural frame.

2. The fluorescent composite molecular probe according to claim 1, characterized in that: The number of donor molecules in the FRET fluorescence unit is smaller than that of acceptor molecules.

3. The fluorescent composite molecular probe according to claim 2, characterized in that: When the number of donor molecules in the FRET fluorescent unit is 1, the number of acceptor molecules is ≥2; or, when the number of donor molecules in the FRET fluorescent unit is 2, the number of acceptor molecules is ≥3; or, when the number of donor molecules in the FRET fluorescent unit is 3, the number of acceptor molecules is ≥4.

4. The fluorescent composite molecular probe according to claim 1, characterized in that: The nucleic acid chain is selected from a deoxyribonucleic acid chain, a ribonucleic acid chain, a peptide nucleic acid chain or a threose nucleic acid chain.

5. The fluorescent composite molecular probe according to claim 4, characterized in that: When the structural framework is a nucleic acid chain, the donor molecule and the acceptor molecule in the FRET fluorescent unit are connected to the same nucleotide or to different nucleotides with a gap; preferably, the gap between the donor molecule and the acceptor molecule in the FRET fluorescent unit is 0-15 bp; and / or, the gap between each FRET fluorescent unit in the fluorescent composite molecular probe is 5-35 bp.

6. The fluorescent composite molecular probe according to claim 4, characterized in that: The structural framework is a linear, two-dimensional multi-chain, two-dimensional plane or three-dimensional structure composed of nucleic acid chains or polypeptide chains; preferably, the structural framework is selected from DNA chain structures, plane or three-dimensional nanostructures formed by self-assembly through base complementary pairing; more preferably, the structural framework is a double-stranded structure composed of two nucleic acid chains, a stem-loop structure formed by a single chain, or a stem-loop structure, a triplex structure, a quadruplex structure, a multi-chain cross structure, a pillar structure, or a polyhedron structure formed by multiple nucleic acid chains; or, a DNA three-dimensional structure formed by DNA origami technology is a plane or three-dimensional structure composed of one or more single-stranded circular nucleic acid chains as a scaffold and multiple short-chain nucleic acid chains; the plane structure is selected from a plane triangle or a plane polygon, and the three-dimensional structure is selected from a regular polyhedron or a polygonal three-dimensional wireframe.

7. The fluorescent composite molecular probe according to claim 1, characterized in that: The emission spectrum of the donor molecule overlaps with the absorption spectrum of the acceptor molecule.

8. A labeling molecule, characterized in that The labeling molecule comprises a fluorescent composite molecular probe and a probe-binding substrate as described in any one of claims 1-7, wherein the fluorescent composite molecular probe binds to the probe-binding substrate in a covalent or non-covalent manner, and the probe-binding substrate is selected from amino acids or amino acid derivatives, polypeptide chains, nucleotides or nucleotide derivatives or nucleic acid chains.

9. Use of the fluorescent composite molecular probe according to any one of claims 1 to 7 or the labeling molecule according to claim 8 in preparing sequencing products, molecular diagnosis or molecular detection products.

10. The use according to claim 9, characterized in that The sequencing product, molecular diagnosis or molecular detection product is selected from one or more of a DNA sequencing product, an RNA sequencing product, a DNA / RNA detection product, a protein detection product, an antigen detection product or an antibody detection product.

Citation Information

Cited By

  • Preparation and application of multicolor nano fluorescent probe based on fluorescent micromolecule FRET (Fluorescence Resonance Energy Transfer)

    CN122012083A